DDInter1840 DDInter62
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Trabectedin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Trabectedin {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Trabectedin {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Ambrisentan
Trabectedin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Ambrisentan
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Trabectedin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Trabectedin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Trabectedin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Trabectedin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Ambrisentan
Trabectedin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Ambrisentan